Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26075
Title: The therapeutic potential of GLP-1 analogues for stress-related eating and role of GLP-1 in stress, emotion and mood: a review.
Austin Authors: Hreins, Eva Guerrero;Goldstone, Anthony P;Brown, Robyn M;Sumithran, Priya 
Affiliation: Endocrinology
The Florey Institute of Neuroscience and Mental Health, Mental Health Theme, Parkville, Melbourne, Australia
The Florey Department of Neuroscience and Mental Health, University of Melbourne, Parkville, Melbourne, Australia
PsychoNeuroEndocrinology Research Group, Centre for Neuropsychopharmacology, Division of Psychiatry, and Computational, Cognitive and Clinical Neuroimaging Laboratory, Department of Brain Sciences, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, UK
Department of Medicine (St Vincent's), University of Melbourne, Victoria, Australia
Issue Date: 16-Mar-2021
Date: 2021-03-16
Publication information: Progress in Neuro-Psychopharmacology & Biological Psychiatry 2021; online first: 16 March
Abstract: Stress and low mood are powerful triggers for compulsive overeating, a maladaptive form of eating leading to negative physical and mental health consequences. Stress-vulnerable individuals, such as people with obesity, are particularly prone to overconsumption of high energy foods and may use it as a coping mechanism for general life stressors. Recent advances in the treatment of obesity and related co-morbidities have focused on the therapeutic potential of anorexigenic gut hormones, such as glucagon-like peptide 1 (GLP-1), which acts both peripherally and centrally to reduce energy intake. Besides its appetite suppressing effect, GLP-1 acts on areas of the brain involved in stress response and emotion regulation. However, the role of GLP-1 in emotion and stress regulation, and whether it is a viable treatment for stress-induced compulsive overeating, has yet to be established. A thorough review of the pre-clinical literature measuring markers of stress, anxiety and mood after GLP-1 exposure points to potential divergent effects based on temporality. Specifically, acute GLP-1 injection consistently stimulates the physiological stress response in rodents whereas long-term exposure indicates anxiolytic and anti-depressive benefits. However, the limited clinical evidence is not as clear cut. While prolonged GLP-1 analogue treatment in people with type 2 diabetes improved measures of mood and general psychological wellbeing, the mechanisms underlying this may be confounded by associated weight loss and improved blood glucose control. There is a paucity of longitudinal clinical literature on mechanistic pathways by which stress influences eating behavior and how centrally-acting gut hormones such as GLP-1, can modify these. (250).
URI: https://ahro.austin.org.au/austinjspui/handle/1/26075
DOI: 10.1016/j.pnpbp.2021.110303
Journal: Progress in Neuro-Psychopharmacology & Biological Psychiatry
PubMed URL: 33741445
Type: Journal Article
Subjects: Addiction
Emotion
GLP-1
Mood
Stress
obesity
Appears in Collections:Journal articles

Show full item record

Page view(s)

46
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.